Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer
Journal
Journal of Thoracic Oncology
Journal Volume
12
Journal Issue
10
Pages
1552-1560
Date Issued
2017
Author(s)
Ou S.-H.I
De Petris L
Gadgeel S
Gandhi L
Kim D.-W
Barlesi F
Govindan R
Dingemans A.-M.C
Crino L
Lena H
Popat S
Ahn J.S
Dansin E
Golding S
Bordogna W
Balas B
Morcos P.N
Zeaiter A
Shaw A.T.
Abstract
Introduction Alectinib demonstrated clinical efficacy and an acceptable safety profile in two phase II studies (NP28761 and NP28673). Here we report the pooled efficacy and safety data after 15 and 18 months more follow-up than in the respective primary analyses. Methods Enrolled patients had ALK receptor tyrosine kinase gene (ALK)-positive NSCLC and had progressed while taking, or could not tolerate, crizotinib. Patients received oral alectinib, 600 mg twice daily. The primary end point in both studies was objective response rate assessed by an independent review committee (IRC) using the Response Evaluation Criteria in Solid Tumors, version 1.1. Secondary end points included disease control rate, duration of response, progression-free survival, overall survival, and safety. Results The pooled data set included 225 patients (n = 138 in NP28673 and n = 87 in NP28761). The response-evaluable population included 189 patients (84% [n = 122 in NP28673 and n = 67 in NP28761]). In the response-evaluable population, objective response rate as assessed by the IRC was 51.3% (95% confidence interval [CI]: 44.0–58.6 [all PRs]), the disease control rate was 78.8% (95% CI: 72.3–84.4), and the median duration of response was 14.9 months (95% CI: 11.1–20.4) after 58% of events. Median progression-free survival as assessed by the IRC was 8.3 months (95% CI: 7.0–11.3) and median overall survival was 26.0 months (95% CI: 21.4–not estimable). Grade 3 or higher adverse events (AEs) occurred in 40% of patients, 6% of patients had treatment withdrawn on account of AEs, and 33% had AEs leading to dose interruptions/modification. Conclusions This pooled data analysis confirmed the robust systemic efficacy of alectinib in ALK-positive NSCLC with a durable response rate. Alectinib also had an acceptable safety profile with a longer duration of follow-up. ? 2017 International Association for the Study of Lung Cancer
Subjects
Alectinib; Non–small cell lung cancer; NP28673; NP28761; Pooled analysis
SDGs
Other Subjects
alanine aminotransferase; alectinib; alkaline phosphatase; aspartate aminotransferase; creatine kinase; crizotinib; protein tyrosine kinase; receptor tyrosine kinase ALK; unclassified drug; alectinib; carbazole derivative; piperidine derivative; adult; aged; alanine aminotransferase blood level; ALK gene; alkaline phosphatase blood level; anemia; arthralgia; Article; aspartate aminotransferase blood level; backache; bilirubin blood level; bleeding; cancer control; cancer growth; cancer survival; constipation; controlled study; coughing; creatine kinase blood level; death; decreased appetite; diarrhea; dizziness; drug efficacy; drug safety; drug tolerance; dyspnea; endocarditis; fatigue; female; follow up; gene; headache; human; hyperbilirubinemia; hypertransaminasemia; hypertriglyceridemia; hypokalemia; insomnia; intestine perforation; lung embolism; major clinical study; male; multicenter study (topic); myalgia; nausea; non small cell lung cancer; open study; oropharynx pain; overall survival; peripheral edema; phase 2 clinical trial (topic); photosensitivity; priority journal; progression free survival; rash; rhinopharyngitis; treatment duration; treatment response; upper abdominal pain; upper respiratory tract infection; vomiting; weight gain; clinical trial; lung tumor; middle aged; multicenter study; non small cell lung cancer; pathology; phase 2 clinical trial; treatment outcome; Adult; Aged; Carbazoles; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Treatment Outcome
Publisher
Elsevier Inc
Type
journal article